Key result
Four novel hub genes show strong diagnostic accuracy with AUC >0.8 for ARVC.
Why the study?
Arrhythmogenic right ventricular cardiomyopathy involves a complex gene interaction network that influences diagnosis and prognosis, warranting identification of crucial genes and pathways.
p-value: p=< 0.05
These hub genes may support ARVC biomarker research; leaves open diagnostic adoption pending validation in larger human cohorts.
As one common disease causing young people to die suddenly due to cardiac arrest, arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disorder of heart muscle whose progression covers one complicated gene interaction network that influence the diagnosis and prognosis of it. In our research, differentially expressed genes (DEGs) were screened, and we established a weighted gene coexpression network analysis(WGCNA) and gene set net correlations analysis (GSNCA) for identifying crucial genes as well as pathways related to ARVC pathogenic mechanism (n = 12). In the research, the results demonstrated that there were 619 differentially expressed genes (DEGs) in total between non-failing donor myocardial samples and ARVC tissues (FDR < 0.05). WGCNA analysis identified the two gene modules (brown and turquoise) as being most significantly associated with ARVC state. Then the ARVC-related 4 key biological pathways (cytokine-cytokine receptor interaction, chemokine signaling pathway, neuroactive ligand receptor interaction, JAK-STAT signaling pathway) and 4 hub genes (CXCL2, TNFRSF11B, LIFR and C5AR1) in ARVC samples were further identified by GSNCA method. Finally, we used t-test and receiver operating characteristic (ROC) curves for validating hub genes, results showed significant differences in t-test and their AUC areas all greater than 0.8. Together, these results revealed that the new 4 hub genes as well as key pathways that might be involved into ARVC diagnosis. Even though further experimental validation is required for the implication by association, our findings demonstrate that the computational methods based on systems biology might complement the traditional gene-wide approaches, as such, might offer a new insight in therapeutic intervention within rare diseases of people like ARVC.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2018) studied Arrhythmogenic right ventricular cardiomyopathy (ARVC) (n=12). Arrhythmogenic right ventricular cardiomyopathy (ARVC) vs. Non-failing donor hearts was evaluated on Differentially expressed genes and hub genes associated with ARVC (p=< 0.05). Coexpression analysis identified 619 differentially expressed genes and 4 hub genes (CXCL2, TNFRSF11B, LIFR, and C5AR1) with AUC > 0.8 that may serve as diagnostic biomarkers for ARVC.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: